Work Package Relationships: A Visual Overview

WP1: Project management and oversight

Description

WP1 deals with overall Project Coordination, Project Management, Financial Management, and Risk Management.

In addition, it focuses on development of strategies and long-term project plans, and ensures that work complies with national and EU Health and Safety regulations and Ethical Guidelines.

Objectives

• Establish management committees and guidelines for their operation

• Establish technical and financial reporting guidelines, monitoring and reporting

• Administration of Consortium Agreement

• Delivery of all necessary reports including periodic and final project reports

Academic Lead
Industry Co-Lead
(2023-2024)
Industry Co-Lead
(2019-2023)
Project Manager
EFPIA Project Manager
Lynn Rochester

Professor of Human Movement Science

Institute of Neuroscience, Newcastle University

Daniel Rooks

Executive Director, Clinical Excellence Head, Endpoint Management Program

DISCOVERY & PROFILING / Translational Medicine
Novartis

Ronenn Roubenoff

MD, MHS, Global Head, Translational Medicine Discovery & Profiling, Global Head, Musculoskeletal Disease Translational Medicine

Novartis

Mike Jackson

Project and Business Development Manager

iXscient

Tilo Hache

Strategy & Planning Lead, Translational Medicine Discovery & Profiling

Novartis

WP2: Algorithm development and technical validation

Description

WP2 produces a validated ‘device-algorithm pair’ and associated technical, clinical and patient specific standards for clinical validation in WP4.

A comprehensive approach is adopted to achieve a robust technical validation, including validation on real world data. Current state of the art modelling of human gait will be combined with advanced processing techniques to increase the specificity and accuracy of algorithms. A range of human factors will be assessed related to sensor and protocol acceptability.

Objectives

• Create a database of existing real-world and laboratory data and algorithms for the quantification of digital mobility outcomes

• Optimise algorithms for digital mobility outcomes and confounding factors from different mobility sensors and locations

• Provide a validated device-algorithm pair to be used in WP4

• Assess additional factors, such as user characteristics and comfort, wearability and protocol acceptability, for the chosen mobility sensor solution

• Provide protocols, standards, manuals, technical validation datasets, sensor requirements and algorithm specifications

Academic Lead (2024)
Academic Lead (2022-2023)
Academic Lead (2019-2022)
Industry Co-Lead

Professor of Bioengineering
Polytechnic University of Torino

Silvia Del Din

Newcastle University Academic Track Fellow Translational and Clinical Research Institute

Newcastle University

Claudia Mazzà

Professor of Biomechanics

University of Sheffield

Arne Mueller

Data Scientist, Clinical Digital Endpoints

Novartis

WP3: Database development and data management

Description

WP3 is responsible for design and implementation of the end-to-end data storage and management platform.

It primarily underpin and enable the activities of WP2 and WP4, as the principal aim of WP3 is to provide a facility for managing and storing the data generated during these WPs.

Objectives

• Define and implement the standard for clinical and technical data acquisition, anonymisation, quality check and processing

• Specify and develop end-to-end multimodal data hosting, management and maintenance platform

• Implement and test the database management and data processing platform

• Provide a data management platform that meets the specific needs for data security, privacy and secure data transfer

• Produce and maintain the suite of software tools that are required for successful data capture in WP4

Academic Lead
Industry Co-Lead
Brian Caulfield

Professor of Physiotherapy, Director INSIGHT Centre for Data Analytics

University College Dublin

Gerard Quinn

VP, IT Innovation & Informatics

ICON

WP4: Definition and validation of digital mobility
outcomes against clinical endpoints

Description

WP4 carries out the clinical validation where digital mobility outcomes are linked to clinical end-points. This is achieved through the Mobilise-D prospective longitudinal cohort study that incorporates four disease cohorts: chronic obstructive pulmonary disease (COPD), Parkinson’s disease (PD), multiple sclerosis (MS) and proximal femoral fracture (PFF).

Digital mobility outcomes are tested as predictors of mobility, disability, falls, hospitalisation, nursing home admission and mortality.

Objectives

• Finalise the network of disease cohorts for recruitment into the Mobilise-D cohort study

• Refine the clinical assessment protocol for each disease cohort and the harmonised protocol for the Mobilise-D cohort

• Complete recruitment and longitudinal data collection in prospective Mobilise-D
cohort study

• Establish clinical validity of digital mobility outcomes to predict clinical end-points in each disease cohort and the global Mobilise-D cohort

• Provide clinical expertise in the planning of data analysis and data interpretation

• Produce and maintain the suite of software tools that are required for successful data capture in WP4

Academic Lead
Industry Co-Lead
Industry Co-Lead
Clemens Becker

MD, Head of Department Geriatric Medicine, Orthogeriatrics and Geriatric Rehabilitation, Research Group Clinical Gerontology

Robert Bosch Gesellschaft Fur Medizinische
Forschung

Ram Miller

Senior Translational Medicine Expert, Musculoskeletal Disease

Novartis Institutes for BioMedical Research

Paolo Piraino

Expert Biomarker & Data Insights

Bayer AG

WP5: Regulatory, HTA and payer consensus over operational definitions

Description

WP5 aims to foster acceptance by global health authorities, and health technology assessment bodies of the routine use of wearable mobility sensors in the safety and efficacy testing of new medicinal products, and in the clinical practice as a technology to support medical decision and management of individual patients.

Objectives

• Pursue with the competent authorities (e.g. the European Medicines Agency in Europe, the Food & Drugs Administration in USA) the regulatory qualification of Digital Mobility Outcomes obtained with wearable sensors for the use in the regulatory evaluation of new drugs.

• Engage with national and European authorities to demonstrate how the use of digital mobility outcomes can help to better evaluate the socioeconomic impact of new drugs.

Academic Lead
Industry Co-Lead
Marco Viceconti

Professor of Computational Biomechanics, Department of Industrial Engineering

Alma Mater Studiorum – Università di Bologna

Wim Dartee

Global Lead Medical Devices and Combination Products, Regulatory Affairs Innovation

Novartis Pharma AG, Basel

WP6: Statistical analysis, evaluation of results and data availability

Description

WP6 analyses and validates digital mobility outcomes for the disease cohorts assessed and followed in WP4, with the aim to provide complete information for regulatory qualification.

The validation covers construct validity, predictive capacity, responsiveness, ability to detect changes and identify a minimal important difference for improvement or worsening of the digital mobility outcomes.

Objectives

• Pursue with the competent authorities (e.g. the European Medicines Agency in Europe, the Food & Drugs Administration in USA) the regulatory qualification of Digital Mobility Outcomes obtained with wearable sensors for the use in the regulatory evaluation of new drugs.

• Engage with national and European authorities to demonstrate how the use of digital mobility outcomes can help to better evaluate the socioeconomic impact of new drugs.

Academic Lead
Industry Co-Lead
Judith Garcia-Aymerich

Research Professor, Head of the Non-Communicable Diseases and Environment Research Programme

Fundacion Privada Instituto De Salud Global

Guido Thömmes

Associate Director, Biostatistician Global Biostatistics, Clinical Measurement Sciences, R&D, Healthcare

Merck KGaA, Darmstadt

WP7: Stakeholder information and results dissemination and exploitation

Description

WP7s main goals are to drive public awareness of the project by disseminating, teaching, and spreading the outcomes and results of the project. To promote access and use of project results, we create and implement procedures to make data, standards, and software openly accessible.

To ensure sustainability after the life of the project, a digital mobility assessment module will be developed and provided that will enable external researchers and industry to include real-world mobility assessment in future studies and trials.

Objectives

• Drive public awareness of the Mobilise-D project by disseminating, teaching,
and spreading the outcomes and results of the project

• Engage the community and create a project Stakeholders Network

• Organise and participate in events to inform the relevant stakeholders and public
at large about project results and outcomes

• Create procedures to make data, standards, and software openly accessible

• Develop a strategy for exploitation and translation of project results into practice

• Ensure optimal exploitation and sustainability by providing user-friendly mobility
assessment modules

Academic Lead
Industry Co-Lead
Industry Co-Lead
Beatrix Vereijken

Professor of Human Movement Science, Department of Neuromedicine and Movement Science

Norwegian University of Science and Technology

Valdo Arnera

MD, Scientific Advisor and General Manager

Clario Geneva

Nadir Ammour

Global Lead Clinical Innovation and Partnership, Patients and Sites

Sanofi